Printer Friendly
The Free Library
14,488,716 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Meiji Dairies, Kyowa Hakko Kogyo Receive Approval for MRI Digestive Tract Contrast Medium BOTHDEL.


Tokyo, Japan, Apr 26, 2006 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
) - Meiji Dairies and Kyowa Hakko Kogyo have obtained approval for BOTHDEL Oral Solution, an oral MRI 1. (application) MRI - Magnetic Resonance Imaging.
2. MRI - Measurement Requirements and Interface.
 contrast medium for the gastrointestinal tract gastrointestinal tract
n.
The part of the digestive system consisting of the stomach, small intestine, and large intestine.


Gastrointestinal tract 
, from the Ministry of Health, Labor and Welfare.

The new product, which can exert good contrast effects, will make a contribution to abdominal diagnostic imaging.

BOTHDEL is scheduled to be available around October after being listed on the NHI NHI
abbr.
National Health Insurance
 drug price list. Meiji Dairies will manufacture the agent while Kyowa Hakko Kogyo will handle marketing.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Apr 27, 2006
Words:93
Previous Article:Nihon Nohyaku Receives Approval for Lanoconazole, Antifungal Agent for Athlete's Foot.
Next Article:Dainippon Sumitomo Pharma Announces Results of Clinical Trial of Mosapride Citrate.



Related Articles
Kyowa Hakko Kogyo, Mitsubishi Pharma Obtain Additional Approval for Recombinant Alteplase Agents.
Kyowa Hakko Kogyo to Release Plant-derived Glucosamine for Commercial Use in September.
Kyowa Hakko Chemical to Increase Production Capacity of 2-Ethyl Hexanoic Acid.
Kyowa Hakko Kogyo Licenses Anti-tumor Drug Candidate Mitotic Kinesin Eg5 Inhibitor to Eli Lilly.
Kyowa Hakko Kogyo to Introduce Self-Injectable Drug for Treating Parkinson's Disease from Britannia Pharmaceuticals.
Kyowa Hakko Kogyo Completes Overseas Phase III Clinical Trials for KW-6002, Anti-Parkinson's Disease Agent.
Kyowa Hakko Kogyo to Expand Its Fuji Plant and Accelerate R&D for Antibody Drugs.
Alcon Japan, Kyowa Hakko Kogyo to Join Hands in Sales and Promotion of Olopatadine Hydrochloride Ophthalmic Solution.
Kyowa Hakko Licenses Anticancer Agent KW-2401 to Keryx Biopharmaceuticals.
Zeria, Kyowa Hakko in Japan Co-development and Co-marketing Agreement for Asacol(R) for Inflammatory Bowel Disease.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles